Biomerica (BMRA) Cost of Revenue (2010 - 2026)

Biomerica has disclosed Cost of Revenue across 17 years of filings, most recently posting $1.0 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1.0 million, up 216.26% year-over-year; the trailing twelve-month figure through Feb 2026 was $6.7 million (up 62.04% YoY), and the FY2025 annual result was $4.8 million, changed 0.19% from the prior year.
• Cost of Revenue came in at $1.0 million for Q1 2026 at Biomerica, down from $1.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $6.0 million in Q1 2022 to a low of $326000.0 in Q1 2025.
• The 5-year median for Cost of Revenue is $1.2 million (2024), against an average of $1.8 million.
• Across the five-year window, Cost of Revenue surged 349.58% in 2022 and tumbled 83.45% in 2023, its largest moves.
• Biomerica's Cost of Revenue stood at $1.1 million in 2022, then climbed by 9.91% to $1.2 million in 2023, then fell by 3.46% to $1.2 million in 2024, then decreased by 3.34% to $1.2 million in 2025, then fell by 11.04% to $1.0 million in 2026.
• The last three Cost of Revenue figures came in at $1.0 million (Q1 2026), $1.2 million (Q4 2025), and $956000.0 (Q3 2025), per Business Quant data.